WO2020009132A1 - ジアリールピリジン誘導体の製造方法 - Google Patents
ジアリールピリジン誘導体の製造方法 Download PDFInfo
- Publication number
- WO2020009132A1 WO2020009132A1 PCT/JP2019/026395 JP2019026395W WO2020009132A1 WO 2020009132 A1 WO2020009132 A1 WO 2020009132A1 JP 2019026395 W JP2019026395 W JP 2019026395W WO 2020009132 A1 WO2020009132 A1 WO 2020009132A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- added
- formula
- mixture
- compound represented
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
- B01J23/44—Palladium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B61/00—Other general methods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a novel method for producing a diarylpyridine derivative, and particularly to a production method including a novel method for synthesizing a pyridine ring without using palladium.
- Patent Document 1 discloses various diarylpyridine derivatives and methods for producing the same.
- a pyridine derivative substituted with a halogen atom is used as a starting compound to introduce an aryl group into a pyridine ring by a coupling reaction using palladium ( For example, in the examples, intermediates 9a and 10a).
- a pyridine derivative in which a plurality of halogen atoms are substituted is expensive, and it is necessary to pay attention to the residual palladium in the target substance when palladium is used a plurality of times.
- Non-Patent Documents 1, 2, and 3 A method of synthesizing a pyridine ring by reacting compound B with a compound having an amino group such as ammonia to synthesize a pyridine ring is known (Non-Patent Documents 1, 2, and 3).
- Non-Patent Document 1 the conversion reaction from compound A to compound B requires a reaction in the presence of a strong base (Non-Patent Documents 2 and 3), and the cyclization reaction of Compound B is performed under high temperature conditions (Non-Patent Documents 1 and 2). 2), in the presence of a large amount of a strong base (Non-patent Document 2), or both of them are necessary (Non-patent Document 3), and the like, which is difficult to handle.
- the present invention relates to a novel method for producing a diarylpyridine derivative, particularly a novel method for synthesizing a pyridine ring without using palladium, a strong base, and a reaction under high temperature, which is an industrially advantageous and novel production method.
- the purpose is to provide.
- the present invention relates to the following (1) to (13).
- step (ii) is oxalyl chloride.
- step (9) The method according to any one of (6) to (8), wherein the base in step (iii) is 2,6-lutidine.
- a sulfate of the compound represented by the formula (VIII) is produced by using the production method described in (13), and then crystallized to give a compound represented by the formula (VIII). To obtain crystals of sulfate of the compound to be obtained.
- Crystals of the sulfate of the compound represented by the formula (VIII) in the present invention can be obtained, for example, by X-ray powder diffraction using CuK ⁇ radiation at 3.71 ⁇ 0.2, 6.48 ⁇ 0.2, 7.37. ⁇ 0.2, 9.80 ⁇ 0.2, 10.29 ⁇ 0.2, 11.01 ⁇ 0.2, 18.44 ⁇ 0.2, 20.53 ⁇ 0.2, 22.91 ⁇ 0 And a crystal having at least five peaks at a diffraction angle (2 ⁇ ) selected from 0.2 and 24.15 ⁇ 0.2.
- a novel method for synthesizing a pyridine ring without using palladium, a strong base, and a reaction under high temperature can be provided.
- iminium salts that required a reaction using a strong base at ultra-low temperature or a reaction at high temperature for synthesis
- a method that can be synthesized under extremely mild reaction conditions we found a method that can be synthesized under extremely mild reaction conditions.
- a synthesis method that does not require a conventional reaction using a strong base or a reaction under high temperature conditions can be provided.
- FIG. 9 is a view showing an XRD chart of compound (26) described in Example 7.
- FIG. 9 is a view showing an XRD chart of compound (26) described in Example 7.
- the “chlorinating agent” may be any as long as it reacts with dimethylformamide to generate a Vilsmeier reagent, and examples thereof include chlorine, oxalyl chloride, thionyl chloride, and phosphorus oxychloride. Preferably, it is oxalyl chloride.
- the "base” used in producing the compound represented by the formula (IV) or a salt thereof may be any one that can extract a benzyl-position proton of the compound represented by the formula (III),
- DBU 1,8-diazabicyclo [5.4.0] undec-7-ene
- DIPEA N, N-diisopropylethylamine
- DABCO 1,4-diazabicyclo [2.2.2] octane
- Triethylamine pyridine, 2,6-lutidine, N-methylmorpholine, tetramethylethylenediamine (TMEDA) and the like.
- ⁇ The“ palladium carbon catalyst ” that can be used in the present invention may be any palladium carbon catalyst that can be used in a debenzylation reaction and a reduction reaction from a nitro group to an amino group.
- M Korean Fine Chemical
- PH Korean Fine Chemical
- PE type NE Chemcat
- AER type NE Chemcat
- PE ⁇ type ⁇ NE
- examples of the “solvent” that can be used in the reaction using a palladium carbon catalyst include methanol, ethanol, 1-propanol, 1,3-dimethyl-2-imidazolidinone, N-methylpyrrolidone and the like. Preferably, it is 1-propanol or N-methylpyrrolidone.
- “Wittig reagent” means a reagent that can react with an aldehyde and a ketone to form a carbon-carbon double bond.
- a Wittig reagent capable of obtaining a compound in which a double bond is substituted with an alkoxy group is preferable.
- Ph 3 (Cl) CH 2 OMe, Ph 3 (Br) CH 2 OMe, Ph 3 (I) CH 2 OMe and the like can be mentioned.
- the compound represented by the formula (I), the compound represented by the formula (II) or a salt thereof, and the compound represented by the formula (IV) or a salt thereof of the present invention include geometric isomers.
- the compound represented by (VIII) can be converted to a salt by reacting with an acid.
- inorganic salts such as hydrohalides such as hydrofluoride, hydrochloride, hydrobromide and hydroiodide, nitrates, perchlorates, sulfates and phosphates; methane C 1 -C 6 alkyl sulfonates such as sulfonate, trifluoromethane sulfonate, ethane sulfonate, aryl sulfonate such as benzene sulfonate, p-toluene sulfonate, acetate; Organic acid salts such as malate, fumarate, succinate, citrate, ascorbate, tartrate, oxalate and adipate; and glycine, lysine, arginine and ornithine salts , Glutamate and aspartate.
- hydrohalides such as hydrofluoride, hydrochloride, hydrobromide and hydroiodide, nitrates, perch
- ⁇ The“ salt ”in the present invention may include not only a molecule formed through an ionic bond but also a molecule formed through a hydrogen bond or / and a Van der Waals bond.
- water molecules are taken in by being left in the air or recrystallized to form hydrates, and such hydrates are also included in the present invention.
- the compound of the present invention represented by the formula (I), the compound represented by the formula (I ′), the compound represented by the formula (II) or a salt thereof, the compound represented by the formula (III), the compound represented by the formula (IV) Compounds or salts thereof, compounds represented by the formula (V) or salts thereof, compounds represented by the formula (VI) or salts thereof, compounds represented by the formula (VII) or salts thereof, and compounds represented by the formula (VIII)
- the salt may be left in a solvent or recrystallized to absorb a certain solvent to form a solvate, and such a solvate is also included in the present invention. Is done.
- a crystal refers to a solid whose internal structure is formed by the regular repetition of constituent atoms and molecules in three dimensions, and is an amorphous solid or amorphous body having no such a regular internal structure. Is distinguished from
- the fact that the compound represented by the formula (VIII) or a salt thereof is in a crystalline form is confirmed by observation with a polarizing microscope, powder X-ray crystal analysis, or single crystal X-ray diffraction measurement. can do. Further, the type of the crystal can be specified by comparing the characteristics of the crystal with data based on each index previously measured. Therefore, according to a preferred embodiment of the present invention, the crystal according to the present invention can be confirmed to be a crystal using such a measuring means.
- the reaction conditions of the present invention should not be construed as being limited thereto.
- the functional group of the compound may be protected with an appropriate protecting group. Examples of such a functional group include a hydroxyl group, a carboxy group, an amino group, and the like.
- the type of the protective group and the conditions for introducing and removing the protective group are, for example, Protective Groups, Organic, Synthesis (T. W. Green and PGM Wuts, John Wiley & Sons, Inc., New York, 2006) can be referred to.
- the measurement conditions of the powder X-ray diffractometer used in the examples are as follows. Measuring range: 3-40 deg Step: 0.020 deg Speed: 10 deg / min Target: Cu (Ka) Tube voltage: 40 kV Tube current: 15 mA Measurement temperature: room temperature (25 ° C)
- the obtained filtrate was concentrated under reduced pressure until the liquid volume became 95 L, and a 1-propanol aqueous solution (1-propanol 19 L, ordinary water 1.9 L) was added dropwise at 40 ° C. Thereafter, the mixture was concentrated under reduced pressure until the liquid volume reached 38 L, and propyl acetate (181 L) was added dropwise at 40 ° C. After stirring at 25 ° C. for 18 hours, the precipitated solid is collected by filtration, washed with a propyl acetate / 1-propanol solution (propyl acetate 51.3 L, 1-propanol 5.7 L), and dried at 40 ° C. under reduced pressure. Thus, the title compound (2) (18.15 kg, yield 94.7%) was obtained as a solid.
- Step 1 Production of (5-methylpyridin-2-yl) propanedinitrile (6) Under a nitrogen atmosphere, N-methylpyrrolidone (7 L) and malononitrile (797 g, 12.1 mol) were added to a reaction vessel. , Sodium tert-butoxide (2.64 kg, 27.4 mol) was added in four portions. Next, 2-chloro-4-methylpyridine (5) (1.40 kg, 11.0 mol) was added, and the concentration of oxygen in the solution was reduced by bubbling with nitrogen. Bistriphenylphosphine palladium dichloride (77.0 g, 0.11 mol) was added, and the mixture was stirred at 55 ° C for 1.5 hours, and then at 80 ° C for 1 hour.
- an aqueous acetic acid solution (1.0 kg of acetic acid, 2.1 kg of ordinary water) was added dropwise at the same temperature, and ordinary water (18.9 kg) was further added and stirred.
- the pH was adjusted to 5.6 with a 6N aqueous hydrochloric acid solution (0.95 kg).
- the precipitated solid was collected by filtration, washed successively with an aqueous solution of N-methylpyrrolidone (1.4 L of N-methylpyrrolidone, 4.2 L of ordinary water) and ordinary water (5.6 L).
- Step 2 Preparation of potassium (5-methylpyridin-2-yl) acetate (2) Under a nitrogen atmosphere, concentrated hydrochloric acid (150 mL) was stirred at 40 ° C. to give (5-methylpyridin-2-yl) propanediene. Nitrile (6) (50 g, 318 mmol) was added in 5 portions every 1 hour. After completion of the addition, the mixture was stirred at 40 ° C for 1 hour, and further stirred at 80 ° C for 1.5 hours. A 48% aqueous solution of potassium hydroxide (241.7 g) was added while maintaining the temperature at -5 ° C or higher and 10 ° C or lower, and the temperature was raised to 25 ° C.
- the solution was filtered while heating at 50 ° C., and washed with 1-propanol (150 mL) at 50 ° C. to remove insolubles.
- Normal water 50 mL was added to the filtrate, and the mixture was concentrated under reduced pressure until the liquid volume reached 200 mL.
- Propyl acetate (400 mL) was added at 40 ° C., and the mixture was concentrated under reduced pressure until the liquid volume reached 200 mL.
- propyl acetate (400 mL) was added at 40 ° C., and the mixture was concentrated under reduced pressure until the liquid volume reached 200 mL.
- the concentrated solution was cooled to 25 ° C., and after further stirring for 1 hour, the precipitated solid was collected by filtration, washed with a propyl acetate / 1-propanol solution (135 mL of propyl acetate, 15 mL of 1-propanol), and washed at 40 ° C. By drying under reduced pressure, the title compound (2) (57.05 g, yield 94.8%) was obtained as a solid.
- acetonitrile (257 L) and potassium (5-methylpyridin-2-yl) acetate (2) (17.15 kg, 90.6 mol) were added to the reaction vessel, and the mixture was heated and refluxed at 82 ° C. for 2 hours. .
- the mixture was concentrated under normal pressure until the liquid volume reached 86 L, and acetonitrile (171.5 L) was added at 25 ° C.
- pyridine hydrochloride (12.57 kg, 109 mol) was added and stirred for 30 minutes.
- carbonyldiimidazole (16.16 kg, 100 mol) was added and stirred for 40 minutes.
- Liquid separation was carried out at about 50 ° C., and the aqueous layer was discarded, followed by washing with a 10% aqueous sodium chloride solution (20 mL). After liquid separation at 50 ° C. and discarding the aqueous layer, the mixture was cooled to room temperature, 32.5 mL of a 2N aqueous hydrochloric acid solution was added, and the mixture was stirred for about 5 minutes. After the separated organic layer was discarded, 32.5 mL of toluene was added, the pH was adjusted to about pH 5 with a 25% aqueous sodium chloride solution, and the mixture was stirred for about 5 minutes.
- the ethyl 4- (5-methylpyridin-2-yl) -3-oxobutanoate (7) solution was desalted and filtered, and added dropwise to the reaction vessel at 60 ° C. for about 1 hour.
- the mixture was washed with toluene (6.5 mL) and stirred at 60 ° C. for 2 hours. Subsequently, the operation of concentrating under reduced pressure until the liquid volume reached 32.5 mL and adding toluene (32.5 mL) was repeated four times.
- the solution was concentrated under reduced pressure again until the liquid volume became 32.5 mL, and 1- (tetrahydro-2H-pyran-4-yl) methanamine (3.96 g, 0.034 mol) was added at 25 ° C.
- seed crystal (9) (7 mg) was added. After confirming the crystallization, the mixture was cooled to -5 ° C and stirred overnight. The precipitated solid was collected by filtration, washed with toluene (20 mL) cooled to -5 ° C, and dried at 40 ° C under reduced pressure to give the title compound (9) (5.87 kg, yield 47.5%). Obtained as a solid. * Seed (9) was obtained by partially collecting the reaction solution and concentrating it under reduced pressure.
- N, N-dimethylacetamide (5.00 L) was stirred at 25 ° C., and potassium carbonate (0.956 kg, 6.92 mol) and 1,2-difluoro-4-nitrobenzene (11) ( After adding 1.00 kg, 6.29 mol) and ethyl cyanoacetate (0.782 kg, 6.91 mol), the temperature was raised to 90 ° C. After stirring at the same temperature for 4 hours, the mixture was cooled to 25 ° C. To this solution was added dropwise normal water (3.50 L) over 30 minutes, followed by 2N aqueous hydrochloric acid (6.91 L) over 15 minutes, and then ethyl acetate (10.0 L) was added. .
- Step 1 Production of (2S) -1,4-dioxan-2-ylmethanol (16) Under a nitrogen atmosphere, 2-chloroethanol (210.0 kg) and boron trifluoride tetrahydrofuran (0.26 kg) were placed in a reaction vessel. kg, 1.86 mol), and the mixture was stirred and heated to 75 ° C.
- (R) -Epichlorohydrin (14) (35.00 kg, 378.3 mol) was added dropwise over 1 hour, and xylene (17.5 L) was added. After stirring at 75 ° C. for 1.5 hours, the mixture was concentrated under reduced pressure to a liquid volume of 70 L.
- Xylene (105.0 L) was added to this solution, and the mixture was concentrated under reduced pressure again to a volume of 70 L. The operation of xylene addition and concentration under reduced pressure was repeated a total of three times.
- the obtained concentrate was cooled to 15 ° C., and a 25% (w / w) aqueous sodium hydroxide solution (302.64 kg, 1.89 kmol) was added. The temperature was raised to 65 ° C, and the mixture was stirred at the same temperature for 5.5 hours, and then cooled to 25 ° C. Toluene (105.0 L) was added to this solution, and the mixture was stirred at 25 ° C. for 5 minutes, allowed to stand, and then the organic layer was discarded.
- 1-Propanol (367.5 L) was added to this solution, and the mixture was concentrated under reduced pressure to a liquid volume of 175 L.
- 1-Propanol (70.0 L) was added to the solution, and the mixture was concentrated under reduced pressure to a liquid volume of 175 L.
- the suspension obtained by concentration was filtered using 1-propanol (175.0 L) to remove precipitated inorganic salts.
- the obtained filtrate was concentrated under reduced pressure to a liquid volume of 30 L, and toluene (52.5 L) was added.
- This suspension was filtered using toluene (17.5 L) to remove precipitated inorganic salts.
- the obtained filtrate was concentrated under reduced pressure to a liquid volume of 30 L, and toluene (70.0 L) was added.
- Step 2 Production of (2R) -1,4-dioxan-2-ylmethyl-methanesulfonate (17)
- (2S) -1,4-dioxan-2-ylmethanol (16) (22.00) kg, 186.2 mol) was added to another reaction vessel, followed by ethyl acetate (440.0 L), triethylamine (26.57 kg, 262.6 mol), methanesulfonyl chloride (32.64 kg, 284). After stirring, the mixture was stirred at 30 ° C. for 1 hour. To this solution was added ordinary water (112.2 L), stirred at 25 ° C. for 15 minutes, allowed to stand, and the aqueous layer was discarded.
- the obtained organic layer was concentrated under reduced pressure to a liquid volume of 40 L.
- Methanol (68.2 L) was added to this solution, and the mixture was concentrated under reduced pressure to a liquid volume of 40 L.
- Methanol (68.2 L) was added to this solution, and the solution was again concentrated under reduced pressure to a volume of 40 L.
- Methanol (220.0 L) was added to this solution, and after cooling to 5 ° C., seed crystal (17) (1 g) was added to precipitate crystals. After crystallization, the mixture was stirred at 5 ° C for 1 hour. Thereafter, the mixture was cooled to ⁇ 15 ° C. over 2 hours and stirred at the same temperature for 24 hours.
- N, N-dimethylacetamide (45.5 L), sodium carbonate (9.96 kg, 93.97 mol) and vanillin (13.00 kg, 85.44 mol) were added, and at 20 ° C. Stir for 5 minutes.
- (2R) -1,4-dioxan-2-ylmethyl-methanesulfonate (17) (17.60 kg, 89.70 mol) was added to the suspension, and the temperature was raised to 120 ° C. Stir for 6.5 hours. After cooling to 70 ° C., ordinary water (97.5 L) was added dropwise over 1 hour while maintaining this temperature. Seed crystals (18) (13 g) were added to this solution to precipitate crystals.
- N-benzyl-5- ⁇ 4-[(2R) -1,4-dioxan-2-ylmethoxy] -3-methoxyphenyl ⁇ -3- (2-fluoro-4-nitrophenyl) pyridine-2 Add amine monohydrochloride (22) (40 g, 0.069 mol), N-methylpyrrolidone (200 mL), 5% Pd / C (TYPE PE, 4.5 g) and apply a pressure of 0.3 MPaG , Three times of nitrogen substitution and hydrogen substitution, respectively. Thereafter, the temperature was raised to 50 ° C., and the mixture was stirred under a pressure of 0.3 MPaH for 1 hour. After the temperature was raised to 70 ° C.
- N, N-dimethylacetamide (35.6 L), 5-methyl-4'-oxo-1 '-(tetrahydro-2H-pyran-4-ylmethyl) -1', 4'-dihydro-2 , 3'-Bipyridine-5'-carboxylic acid (10) (3.56 kg, 10.8 mol) and purified water (152 g) were added, and the mixture was cooled to -8 ° C. Thereafter, thionyl chloride (2.46 kg, 20.7 mol) was added dropwise over 50 minutes, and the mixture was stirred at the same temperature for 1.5 hours.
- N, N-dimethylacetamide (67.5 mL), 5-methyl-4'-oxo-1 '-(tetrahydro-2H-pyran-4-ylmethyl) -1', 4 'are placed in a reaction vessel 1 under a nitrogen atmosphere.
- -Dihydro-2,3'-bipyridine-5'-carboxylic acid (10) (6.72 g, 0.020 mol) was added and cooled to -10 ° C. Thereafter, thionyl chloride (2.55 g, 0.021 mol) was added dropwise over 50 minutes, and the mixture was stirred at the same temperature for 4 hours.
- N, N-dimethylacetamide (49.5 mL), 3- (4-amino-2-fluorophenyl) -5- ⁇ 4-[(2R) -1,4-dioxane- 2-ylmethoxy] -3-methoxyphenyl ⁇ pyridin-2-amine monohydrochloride (23) (9.00 g, 0.019 mol), 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU) (3.11 g, 0.020 mol) was added, and the mixture was stirred at room temperature for 0.5 hour to completely dissolve, and then cooled to ⁇ 10 ° C.
- DBU 1,8-diazabicyclo [5.4.0] undec-7-ene
- the solution in the reaction vessel 2 was added dropwise to the reaction vessel 1 over 1 hour while maintaining the temperature at ⁇ 10 ° C.
- ordinary water (18 mL) was added, and the temperature was raised to 60 ° C.
- Triethylamine was added to this solution to adjust the pH of the solution to 7.5, and then seed crystals (25) (1.0 mg) were added to precipitate crystals.
- the mixture was stirred at 60 ° C. for 3 hours, and water (45.0 mL) was added dropwise over 1 hour while maintaining the same temperature. Then, it cooled to 25 degreeC over 1 hour.
- a 25% aqueous sulfuric acid solution (5.87) was added. g) was added. After confirming the dissolution of the crystals, a filtration operation was performed at the same temperature to remove insolubles, and the crystals were washed with a mixed solution of purified water / acetone (9 mL of purified water and 21 mL of acetone). Thereafter, a 25% aqueous sulfuric acid solution (4.27 g) and a seed crystal (26) (10 mg) were sequentially added to precipitate crystals. After confirming the precipitation of crystals and stirring overnight, purified water (3 mL) was added, and the mixture was heated to 55 ° C. and stirred for 1 hour.
- acetone (40 mL) was added dropwise over 30 minutes. After stirring at 45 ° C. for 30 minutes, acetone (40 mL) was added dropwise over 30 minutes. After stirring at 45 ° C. for 30 minutes, acetone (40 mL) was added dropwise over 30 minutes. After stirring at 45 ° C. for 30 minutes, acetone (40 mL) was added dropwise over 30 minutes. After stirring at 45 ° C. for 30 minutes, acetone (80 mL) was added dropwise over 1 hour. Then, it cooled to 25 degreeC over 60 minutes, and stirred at the same temperature all night.
- the precipitated solid was collected by filtration, the first time the crystals were washed with a mixture of acetone / purified water (44 mL of acetone, 6 mL of purified water), the second time, the crystals were washed with acetone (50 mL), and then washed at 35 ° C. Drying under reduced pressure at 3 kPa gave the title compound (26) (11.95 g) as a solid.
- Seed crystal (26) was obtained by partially collecting the reaction solution and concentrating it under reduced pressure. The obtained crystals were subjected to powder X-ray crystal structure analysis. The results are shown in FIG.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
特許文献1において、種々のジアリールピリジン誘導体およびその製造方法が開示されている。当該文献に開示されているジアリールピリジン誘導体の製造方法は、いずれも、ハロゲン原子が置換したピリジン誘導体を出発化合物として、パラジウムを用いたカップリング反応によりピリジン環にアリール基を導入するものである(例えば、実施例中、中間体9aおよび中間体10a)。しかし、複数のハロゲン原子が置換しているピリジン誘導体は高価であり、複数回のパラジウムの使用は目的物中におけるパラジウムの残留に留意が必要となる。
式(II):
式(III):
式(IV):
式(V):
(ii)工程(i)で得られた化合物を塩素化剤およびジメチルホルムアミドと反応させる工程、
(iii)工程(ii)で得られた化合物を塩基存在下、上記式(III)で示される化合物と反応させる工程、および
(iv)工程(iii)で得られた化合物をベンジルアミンと反応させる工程
を包含する、上記式(V)で示される化合物又はその塩の製造方法。
(7)工程(i)におけるWittig試薬が、Ph3(Cl)CH2OMeである、(6)に記載の方法。
溶媒中、パラジウム炭素触媒存在下、水素と反応させる工程を包含する、
式(VI):
式(VII):
式(VIII):
mg : ミリグラム,g : グラム,kg:キログラム, mL: ミリリットル,L:リットル,mol:モル, MHz : メガヘルツ。
以下の実施例において、核磁気共鳴(以下、1H NMR:500MHz)スペクトルは、テトラメチルシランを標準物質として、ケミカルシフト値をδ値(ppm)にて記載した。分裂パターンは一重線をs、二重線をd、三重線をt、四重線をq、多重線をm、ブロードをbrで示した。
測定範囲:3-40 deg
ステップ:0.020 deg
スピード:10 deg/min
ターゲット:Cu(Ka)
管電圧:40 kV
管電流:15 mA
測定温度:室温(25℃)
(5-メチルピリジン-2-イル)酢酸カリウム(2)の製造
1H NMR (500 MHz, DMSO-d6) : δ= 2.21 (s, 3H), 3.25 (d, J = 3.5 Hz, 2H), 7.16 (d, J = 8.0 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 8.16 (s, 1H).
(5-メチルピリジン-2-イル)酢酸カリウム(2)の製造
(5-メチルピリジン-2-イル)酢酸カリウム(2)の製造
窒素雰囲気下、反応容器にN-メチルピロリドン(7 L)、マロノニトリル(797 g、 12.1 mol)を加え、ナトリウムtert-ブトキシド(2.64 kg、 27.4 mol)を4回に分割して加えた。次に2-クロロ-4-メチルピリジン(5)(1.40 kg、 11.0 mol)を加え、窒素通気することで溶液中の酸素濃度を下げた。ビストリフェニルホスフィンパラジウムジクロリド(77.0 g、 0.11 mol)を加え、55℃で1.5時間攪拌した後、80℃で1時間攪拌した。50℃まで冷却後、同温度下で酢酸水溶液(酢酸1.0 kg、常水2.1 kg)を滴下し、さらに常水(18.9 kg)を加えて攪拌した。25℃に冷却した後、6N塩酸水溶液(0.95 kg)でpHを5.6に調整した。さらに1時間攪拌した後、析出した固体を濾取、N-メチルピロリドン水溶液(N-メチルピロリドン1.4 L、常水4.2 L)、常水(5.6 L)で順次洗浄し、40℃で減圧乾燥することで、標記化合物(6)(1.67 kg、収率96.7%)を固体として得た。
1H NMR (500 MHz, DMSO-d6) : δ= 2.15 (s, 3H), 7.04 (d, J = 9.0 Hz, 1H), 7.63-7.66 (m, 2H), 12.85 (brs, 1H).
窒素雰囲気下、濃塩酸(150 mL)を40℃で攪拌し、(5-メチルピリジン-2-イル)プロパンジニトリル(6)(50 g、 318 mmol)を5分割して1時間おきに加えた。添加終了後40℃で1時間攪拌し、さらに80℃で1.5時間攪拌した。-5℃以上10℃以下に保ちながら48%水酸化カリウム水溶液(241.7 g)を加え、25℃まで昇温後、さらに常水(50 mL)を加えた。50℃まで昇温後、熱時ろ過を行い、50℃の常水(75 mL)で洗浄して不溶物を除去した。得られた溶液は液量が250 mLになるまで減圧濃縮し、45-50℃で1-プロパノール(500 mL)を滴下した。濃塩酸(12.4 mL)を用いてpHを12.6に調整後、液量が250 mLになるまで減圧濃縮し、45-50℃で1-プロパノール(500 mL)を滴下した。再び液量が250 mLになるまで減圧濃縮し、45-50℃で1-プロパノール(500 mL)を滴下した。50℃で熱時ろ過を行い、50℃の1-プロパノール(150 mL)で洗浄し、不溶物を除去した。ろ液に常水(50 mL)を加え液量が200 mLになるまで減圧濃縮した。酢酸プロピル(400 mL)を40℃で加え、液量が200 mLになるまで減圧濃縮した。もう一度、酢酸プロピル(400 mL)を40℃で加え、液量が200 mLになるまで減圧濃縮した。この濃縮液を25℃まで冷却し、さらに1時間攪拌した後、析出した固体を濾取、酢酸プロピル/1-プロパノール溶液(酢酸プロピル135 mL、1-プロパノール15 mL)で洗浄し、40℃で減圧乾燥することで、標記化合物(2)(57.05 g、収率94.8%)を固体として得た。
5-メチル-4′-オキソ-1′-(テトラヒドロ-2H-ピラン-4-イルメチル)-1′,4′-ジヒドロ-2,3′-ビピリジン-5′-カルボン酸エチル(9)の製造
窒素雰囲気下、別の反応釜にN,N-ジメチルホルムアミドジメチルアセタール(76.8 kg、 645 mol)を加え、60℃とした。4-(5-メチルピリジン-2-イル)-3-オキソブタン酸エチル(7)溶液を脱塩ろ過し、60℃で反応釜に加えた。トルエン(17.2 L)で洗浄し、60℃のまま2時間半攪拌した。続いて、液量が86 Lになるまで減圧濃縮し、トルエン(85.8 L)を添加する作業を4回繰り返した。再び液量が86 Lになるまで減圧濃縮し、25℃で1-(テトラヒドロ-2H-ピラン-4-イル)メタンアミン(10.44 kg、 90.6 mol)を添加した。25℃で4時間攪拌後、種晶(9)(2 g)を添加した。起晶確認後、-5℃まで冷却し、16時間攪拌した。析出した固体を濾取、-5℃に冷却したトルエン(51.5 L)で洗浄し、40℃で減圧乾燥することで、標記化合物(9)(17.84 kg、収率55.2%)を固体として得た。
*種晶(9)は、反応溶液を一部採取し、減圧濃縮することで得られた。
1H NMR (500 MHz, DMSO-d6) : δ= 1.24-1.29 (m, 5H), 1.42-1.45 (m, 2H), 1.99-2.02 (m, 1H), 2.32 (s, 3H), 3.26 (dd, J = 10.0, 10.0 Hz, 2H), 3.85 (dd, J = 11.5, 3.0 Hz, 2H), 4.01 (d, J = 7.5 Hz, 2H), 4.22 (q, J = 7.0 Hz, 2H), 7.63 (dd, J = 7.5, 2.5 Hz, 1H), 8.29 (d, J = 2.5 Hz, 1H), 8.43 (s, 1H), 8.44 (s, 1H), 8.49 (d, J = 2.5 Hz, 1H).
5-メチル-4′-オキソ-1′-(テトラヒドロ-2H-ピラン-4-イルメチル)-1′,4′-ジヒドロ-2,3′-ビピリジン-5′-カルボン酸エチル(9)の製造
窒素雰囲気下、別の反応容器にN,N-ジメチルホルムアミドジメチルアセタール(29.12 g、 0.244 mol)を加え、60℃とした。4-(5-メチルピリジン-2-イル)-3-オキソブタン酸エチル(7)溶液を脱塩ろ過し、60℃で約1時間かけて反応容器に滴下した。トルエン(6.5 mL)で洗浄し、60℃のまま2時間攪拌した。続いて、液量が32.5 mLになるまで減圧濃縮し、トルエン(32.5 mL)を添加する作業を4回繰り返した。再び液量が32.5 mLになるまで減圧濃縮し、25℃で1-(テトラヒドロ-2H-ピラン-4-イル)メタンアミン(3.96 g、 0.034 mol)を添加した。25℃で4時間攪拌後、種晶(9)(7 mg)を添加した。起晶確認後、-5℃まで冷却し、終夜攪拌した。析出した固体を濾取、-5℃に冷却したトルエン(20 mL)で洗浄し、40℃で減圧乾燥することで、標記化合物(9)(5.87 kg、収率47.5%)を固体として得た。
*種晶(9)は、反応溶液を一部採取し、減圧濃縮することで得られた。
5-メチル-4′-オキソ-1′-(テトラヒドロ-2H-ピラン-4-イルメチル)-1′,4′-ジヒドロ-2,3′-ビピリジン-5′-カルボン酸(10)の製造
1H NMR (500 MHz, DMSO-d6) : δ= 1.29-1.33 (m, 2H), 1.43-1.45 (m, 2H), 2.06-2.07 (m, 1H), 2.36 (s, 3H), 3.27 (dd, J = 10.0, 9.5 Hz, 2H), 3.84 (dd, J = 11.5, 2.5 Hz, 2H), 4.23 (d, J = 7.5 Hz, 2H), 7.72(dd, J = 8.0, 2.5 Hz, 1H), 8.38 (d, J = 8.0 Hz, 1H), 8.53 (d, J = 2.5 Hz, 1H), 8.78 (s, 1H), 8.84 (s, 1H).
(2-フルオロ-4-ニトロフェニル)アセトニトリル(13)の製造
*種晶(13)は、反応溶液を一部採取し、減圧濃縮することで得られた。
1H NMR (500 MHz, CDCl3) : δ= 3.89 (s, 2H), 7.71 (dd, J = 8.5, 8.0 Hz 1H), 8.01 (dd, J = 2.0, 8.5 Hz,, 1H), 8.12 (dd, J = 8.0, 2.0 Hz, 1H).
(2R)-1,4-ジオキサン-2-イルメチル-メタンスルホナート(17)の製造
窒素雰囲気下、反応容器に2-クロロエタノール(210.0 kg)、三フッ化ホウ素テトラヒドロフラン(0.26 kg、 1.86 mol)を添加して攪拌し、75℃まで昇温した。(R)-エピクロロヒドリン(14)(35.00 kg、 378.3 mol)を1時間かけて滴下し、キシレン(17.5 L)を添加した。75℃で1.5時間攪拌した後、液量70 Lまで減圧濃縮した。この溶液にキシレン(105.0 L)を添加し、再び液量70 Lまで減圧濃縮した。キシレン添加、減圧濃縮の操作を合計3回繰り返した。得られた濃縮液を15℃まで冷却し、25%(w/w)水酸化ナトリウム水溶液(302.64 kg、 1.89 kmol)を添加した。65℃まで昇温し、同温度で5.5時間攪拌した後、25℃まで冷却した。この溶液にトルエン(105.0 L)を添加し、25℃で5分攪拌、静置後、有機層を廃棄した。水層に再びトルエン(105.0 L)を添加し、25℃で5分攪拌、静置後、有機層を廃棄した。得られた水層に濃塩酸(127.89 kg)を添加し、pHを7.2に調整した。この溶液に1-プロパノール(175.0 L)を添加し、液量350 Lまで減圧濃縮した。この溶液に1-プロパノール(210.0 L)を添加し、液量290 Lまで減圧濃縮した。この溶液に1-プロパノール(297.5 L)を添加し、液量210 Lまで減圧濃縮した。この溶液に1-プロパノール(367.5 L)を添加し、液量175 Lまで減圧濃縮した。この溶液に1-プロパノール(70.0 L)を添加し、液量175 Lまで減圧濃縮した。濃縮で得られた懸濁液を1-プロパノール(175.0 L)を用いて濾過し、析出している無機塩を除去した。得られた濾液を液量30 Lまで減圧濃縮し、トルエン(52.5 L)を添加した。この懸濁液をトルエン(17.5 L)を用いて濾過し、析出している無機塩を除去した。得られた濾液を液量30 Lまで減圧濃縮し、トルエン(70.0 L)を添加した。さらに液量約20 Lまで減圧濃縮を行い、標記化合物(16)(22.47 kg、収率45.3%)を得た。
1H NMR (500MHz, DMSO-d6) : δ= 3.26 (dd, J = 10.0, 11.5 Hz, 1H), 3.25-3.49 (m, 4H), 3.54 (ddd, J = 2.5, 11.0, 11.5 Hz, 1H), 3.62 (dd, J = 2.5, 11.5 Hz, 1H), 3.68 (dd, J = 3.0, 11.5 Hz, 1H), 3.73 (dd, J = 2.5, 11.0 Hz, 1H), 4.68 (t, J = 5.5 Hz, 1H).
得られた(2S)-1,4-ジオキサン-2-イルメタノール(16)(22.00 kg、 186.2 mol)を別の反応容器に添加し、続けて酢酸エチル(440.0 L)、トリエチルアミン(26.57 kg、 262.6 mol)、メタンスルホニルクロリド(32.64 kg、 284.9 mol)を添加後、30℃で1時間攪拌した。この溶液に常水(112.2 L)を添加し、25℃で15分攪拌、静置後、水層を廃棄した。得られた有機層を液量40 Lまで減圧濃縮した。この溶液にメタノール(68.2 L)を添加し、液量40 Lまで減圧濃縮した。この溶液にメタノール(68.2 L)を添加し、再び液量40 Lまで減圧濃縮した。この溶液にメタノール(220.0 L)を添加し、5℃まで冷却した後、種晶(17)(1 g)を添加し、結晶を析出させた。結晶析出後、5℃で1時間攪拌した。その後、2時間かけて-15℃まで冷却した後、同温度で24時間攪拌した。析出した固体を濾取、-15℃に冷却したメタノール(88.0 L)で洗浄し、25℃で減圧乾燥することで、標記化合物(17)(21.19 kg、収率63.6%)を固体として得た。
*種晶(17)は、反応溶液を一部採取し、減圧濃縮することで得られた。
1H NMR (500MHz, DMSO-d6) : δ= 3.07 (s, 3H), 3.46 (dd, J = 10.0, 11.5 Hz, 1H), 3.62 (dt, J = 3.0, 11.0 Hz, 1H), 3.70-3.92 (m, 5H), 4.16-4.25 (m, 2H).
4-[(2R)-1,4-ジオキサン-2-イルメトキシ]-3-メトキシベンズアルデヒド(18)の製造
*種晶(18)は、反応溶液を一部採取し、減圧濃縮することで得られた。
1H NMR (500 MHz, DMSO-d6) : δ= 3.40 (dd, J =10.0, 11.0 Hz, 1H), 3.47-3.53 (m. 1H), 3.60-3.70 (m, 2H), 3.74-3.79 (m, 1H), 3.80-3.86 (m, 4H), 3.87-3.93 (m, 1H), 4.03-4.10 (m, 2H), 7.19 (d, J = 8.5 Hz, 1H), 7.40 (d, J = 2.0 Hz, 1H), 7.53 (dd, J = 2.0, 8.5 Hz, 1H), 9.84 (s, 1H).
N-ベンジル-5-{4-[(2R)-1,4-ジオキサン-2-イルメトキシ]-3-メトキシフェニル}-3-(2-フルオロ-4-ニトロフェニル)ピリジン-2-アミン一塩酸塩(22)の製造
*種晶(22)は、反応溶液を一部採取し、減圧濃縮することで得られた。
1H NMR (500MHz, DMSO-d6) : δ= 3.39 (dd, J = 11.5, 10 Hz, 1H), 3.49 (dt, J = 3, 11Hz, 1H), 3.58-3.70 (m, 2H), 3.72-3.78 (m, 1H), 3.79-3.90 (m, 5H), 3.93-4.04 (m, 1H), 5.80 (s, 2H), 7.09 (d, J = 8.5 Hz, 1H), 7.28-7.52 (m, 7H), 7.91 (dd, J = 7.0, 8.0 Hz, 1H), 8.26-8.38 (m, 4H), 8.48 (d, J = 2.5 Hz, 1H), 8.87 (d, J = 1.5 Hz, 1H).
N-ベンジル-5-{4-[(2R)-1,4-ジオキサン-2-イルメトキシ]-3-メトキシフェニル}-3-(2-フルオロ-4-ニトロフェニル)ピリジン-2-アミン一塩酸塩(22)の製造条件検討
3-(4-アミノ-2-フルオロフェニル)-5-{4-[(2R)-1,4-ジオキサン-2-イルメトキシ]-3-メトキシフェニル}ピリジン-2-アミン一塩酸塩(23)の製造
1H NMR (500 MHz, DMSO-d6) : δ= 3.43 (dd, J = 10, 11 Hz, 1H). 3.53 (dt J = 3.0, 11Hz, 1H), 3.64-3.72 (m, 2H), 3.80 (dd, J = 2.0, 11.5Hz, 1H), 3.85-3.92 (m, 5H), 3.97-4.04 (m, 2H), 5.86 (br, 1H), 6.51 (dd, J = 2.0, 12.5 Hz, 1H), 6.57 (dd, J= 2.0, 8.5 Hz, 1H), 7.08 (d, J = 8.5 Hz, 1H), 7.17 (t, J = 8.5 Hz, 1H), 7.26 (dd, J = 2.0, 8.5 Hz, 1H), 7.33 (d, J = 2.0 Hz, 1H), 7.65 (br, 2H), 8.17 (d, J = 2.0 Hz, 1H), 8.37 (d, J = 2.0 Hz, 1H).
3-(4-アミノ-2-フルオロフェニル)-5-{4-[(2R)-1,4-ジオキサン-2-イルメトキシ]-3-メトキシフェニル}ピリジン-2-アミン一塩酸塩(23)の製造
*種晶(23)は、反応溶液を一部採取し、減圧濃縮することで得られた。
N-[4-(2-アミノ-5-{4-[(2R)-1,4-ジオキサン-2-イルメトキシ]-3-メトキシフェニル}ピリジン-3-イル)-3-フルオロフェニル]-5-メチル-4’-オキソ-1’-(テトラヒドロ-2H-ピラン-4-イルメチル)-1’,4’-ジヒドロ-2,3’-ビピリジン-5’-カルボキサミド(25)の製造
*種晶(25)は、反応溶液を一部採取し、減圧濃縮することで得られた。
1H NMR (500 MHz, CDCl3) : δ= 1.42-1.62 (m, 4H), 2.16 (m, 1H), 2.40 (s, 3H), 3.39 (dt, J = 2.0, 12Hz, 2H), 3.55 (dd, J = 12, 10 Hz, 1H), 3.65-3.89 (m, 4H), 3.91 (s, 3H), 3.93-4.10 (m, 8H), 4.55 (br, 2H), 6.96 (d, J = 8.0 Hz, 1H), 7.03 (d, J = 2.0 Hz, 1H), 7.05 (dd, J = 2.0, 8.5 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.50 (dd, J = 2.0, 8.5 Hz, 1H), 7.59 (d, J = 2.5 Hz, 1H), 7.62 (dd, J = 2.5, 8.0 Hz,1H), 7.92 (dd, J = 4.0, 12 Hz, 1H), 8.31 (d, J = 2.0 Hz, 1H), 8.41 (d, J = 2.5 Hz, 1H), 8.47-8.48 (m, 2H), 8.56 (d, J = 2.5 Hz, 1H), 13.01 (s, 1H).
N-[4-(2-アミノ-5-{4-[(2R)-1,4-ジオキサン-2-イルメトキシ]-3-メトキシフェニル}ピリジン-3-イル)-3-フルオロフェニル]-5-メチル-4’-オキソ-1’-(テトラヒドロ-2H-ピラン-4-イルメチル)-1’,4’-ジヒドロ-2,3’-ビピリジン-5’-カルボキサミド(25)の製造
反応容器2に窒素雰囲気下、N、N-ジメチルアセトアミド(49.5 mL)、3-(4-アミノ-2-フルオロフェニル)-5-{4-[(2R)-1,4-ジオキサン-2-イルメトキシ]-3-メトキシフェニル}ピリジン-2-アミン一塩酸塩(23)(9.00 g、 0.019 mol)、1,8-ジアザビシクロ[5.4.0]ウンデカ-7-エン(DBU)(3.11 g、 0.020 mol)を添加し、室温で0.5時間攪拌して完全に溶解させた後、-10℃まで冷却した。
続いて、反応容器1へ反応容器2の溶液を-10℃を維持しながら、1時間かけて滴下した。同温で2時間攪拌した後、常水(18 mL)を添加し、60℃まで昇温した。この溶液にトリエチルアミンを添加し溶液のpHを7.5に調整した後、種晶(25)(1.0 mg)を添加して結晶を析出させた。結晶の析出確認後、60℃で3時間攪拌し、同温度を維持しながら常水(45.0 mL)を1時間かけて滴下した。その後、1時間かけて25℃まで冷却した。同温度で16時間攪拌した後、析出した固体を濾取し、33%N、N-ジメチルアセトアミド水溶液(N、N-ジメチルアセトアミド45.2 mL,常水22.3 mL)と常水(67.5 mL)で順次洗浄して40℃で減圧乾燥することで、標記化合物(25)(13.55g、収率94.5%)を固体として得た。
*種晶(25)は、反応溶液を一部採取し、減圧濃縮することで得られた。
N-[4-(2-アミノ-5-{4-[(2R)-1,4-ジオキサン-2-イルメトキシ]-3-メトキシフェニル}ピリジン-3-イル)-3-フルオロフェニル]-5-メチルー4’-オキソ-1’-(テトラヒドロ-2H-ピラン-4-イルメチル)-1’,4’-ジヒドロ-2,3’-ビピリジン-5’-カルボキサミド硫酸塩水和物(26)の製造
*種晶(26)は、反応溶液を一部採取し、減圧濃縮することで得られた。
得られた結晶について粉末X線結晶構造解析を行った。結果を図1および表2に示す。
1H NMR (500 MHz, DMSO-d6) : δ= 1.37 (dq, J = 4.0, 12 Hz, 2H), 1.52 (d, J = 11.5 Hz, 2H), 2.15 (m, 1H), 2.49 (s, 1H), 3.31 (dt, J = 1.5, 11.5 Hz, 2H), 3.44 (dd, J = 10, 11.5 Hz, 1H), 3.53 (dt, J = 1.5, 11 Hz, 1H), 3.64-3.73 (m, 2H), 3.80 (dd, J = 2.0, 12 Hz, 1H), 3.85-3.92(m, 5H), 3.98-4.05 (m, 2H), 4.26 (d, J = 7.5 Hz, 2H), 7.10 (d, J = 8.5 Hz, 1H), 7.30 (dd, J = 2.5, 8.5 Hz, 1H), 7.36 (d, J = 2.5 Hz, 1H), 7.57-7.62 (m, 2H), 7.77 (br, 2H), 8.04 (dd, J = 2.0, 13 Hz, 1H), 8.11 (br, 1H), 8.38 (dd, J = 2.5, 9.0 Hz, 2H), 8.48 (d, J = 8.5 Hz, 1H), 8.69 (s, 1H), 8.88 (dd, 2.0, 7.0 Hz, 2H), 13.02 (br, 1H).
Claims (13)
- 塩素化剤が、塩化オキザリルである、請求項1に記載の製造方法。
- 塩基が2,6-ルチジンである、請求項3に記載の製造方法。
- 工程(i)におけるWittig試薬が、Ph3(Cl)CH2OMeである、請求項6に記載の方法。
- 工程(ii)における塩素化剤が、塩化オキザリルである、請求項6または7に記載の製造方法。
- 工程(iii)における塩基が、2,6-ルチジンである、請求項6から8のいずれか1項に記載の製造方法。
- 式(V)で示される化合物またはその塩が、式(V)で示される化合物の塩酸塩であり、溶媒が、1-プロパノールまたはN-メチルピロリドンである、請求項10に記載の製造方法。
- 式(VIII)で示される化合物またはその塩が、式(VIII)で示される化合物の硫酸塩である、請求項12に記載の製造方法。
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19831009.6A EP3819296B1 (en) | 2018-07-04 | 2019-07-03 | Method for producing diarylpyridine derivatives |
| CA3105328A CA3105328A1 (en) | 2018-07-04 | 2019-07-03 | Method for producing diarylpyridine derivatives |
| CN201980043226.0A CN112368271A (zh) | 2018-07-04 | 2019-07-03 | 二芳基吡啶衍生物的制造方法 |
| US17/252,469 US11999724B2 (en) | 2018-07-04 | 2019-07-03 | Method for producing diarylpyridine derivatives |
| IL279070A IL279070B2 (en) | 2018-07-04 | 2019-07-03 | A method for the production of diarylpyridine derivatives |
| JP2020529019A JP7337058B2 (ja) | 2018-07-04 | 2019-07-03 | ジアリールピリジン誘導体の製造方法 |
| AU2019299152A AU2019299152A1 (en) | 2018-07-04 | 2019-07-03 | Method for producing diarylpyridine derivatives |
| ES19831009T ES2925365T3 (es) | 2018-07-04 | 2019-07-03 | Método para producir derivados de diarilpiridina |
| JP2023134392A JP2023159297A (ja) | 2018-07-04 | 2023-08-22 | ジアリールピリジン誘導体の製造方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018127197 | 2018-07-04 | ||
| JP2018-127197 | 2018-07-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2020009132A1 true WO2020009132A1 (ja) | 2020-01-09 |
Family
ID=69059540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2019/026395 Ceased WO2020009132A1 (ja) | 2018-07-04 | 2019-07-03 | ジアリールピリジン誘導体の製造方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11999724B2 (ja) |
| EP (1) | EP3819296B1 (ja) |
| JP (2) | JP7337058B2 (ja) |
| CN (1) | CN112368271A (ja) |
| AU (1) | AU2019299152A1 (ja) |
| CA (1) | CA3105328A1 (ja) |
| ES (1) | ES2925365T3 (ja) |
| IL (1) | IL279070B2 (ja) |
| TW (1) | TWI840378B (ja) |
| WO (1) | WO2020009132A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023090337A1 (ja) | 2021-11-19 | 2023-05-25 | 日本曹達株式会社 | 2-ヘテロアリールピリジン化合物の製造方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016006706A1 (ja) | 2014-07-07 | 2016-01-14 | 第一三共株式会社 | テトラヒドロピラ二ルメチル基を有するピリドン誘導体 |
| WO2018174219A1 (ja) * | 2017-03-24 | 2018-09-27 | 第一三共株式会社 | Axl阻害剤とEGFRチロシンキナーゼ阻害薬との併用治療法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2810937T3 (en) | 2012-01-31 | 2017-03-13 | Daiichi Sankyo Co Ltd | PYRIDONE DERIVATIVES |
-
2019
- 2019-07-01 TW TW108123125A patent/TWI840378B/zh not_active IP Right Cessation
- 2019-07-03 JP JP2020529019A patent/JP7337058B2/ja active Active
- 2019-07-03 CA CA3105328A patent/CA3105328A1/en active Pending
- 2019-07-03 AU AU2019299152A patent/AU2019299152A1/en not_active Abandoned
- 2019-07-03 US US17/252,469 patent/US11999724B2/en active Active
- 2019-07-03 EP EP19831009.6A patent/EP3819296B1/en active Active
- 2019-07-03 ES ES19831009T patent/ES2925365T3/es active Active
- 2019-07-03 WO PCT/JP2019/026395 patent/WO2020009132A1/ja not_active Ceased
- 2019-07-03 IL IL279070A patent/IL279070B2/en unknown
- 2019-07-03 CN CN201980043226.0A patent/CN112368271A/zh active Pending
-
2023
- 2023-08-22 JP JP2023134392A patent/JP2023159297A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016006706A1 (ja) | 2014-07-07 | 2016-01-14 | 第一三共株式会社 | テトラヒドロピラ二ルメチル基を有するピリドン誘導体 |
| WO2018174219A1 (ja) * | 2017-03-24 | 2018-09-27 | 第一三共株式会社 | Axl阻害剤とEGFRチロシンキナーゼ阻害薬との併用治療法 |
Non-Patent Citations (9)
| Title |
|---|
| CHURCH, R. ET AL.: "New Synthetic Routes to 3-, 5- , and 6-Aryl-2-chloropyridines", JOURNAL OF ORGANIC CHEMISTRY, vol. 60, no. 12, 1995, pages 3750 - 3758, XP055357318, DOI: 10.1021/jo00117a029 * |
| EGE, G. ET AL.: "A new synthesis of 4- (dimethylamino)-l, 3-butadiene-1, 1- dicarbonitriles and their cyclization to 2-amino- 3-cyanopyridines", SYNTHESIS, vol. 5, 1979, pages 376 - 378, XP001109375, DOI: 10.1055/s-1080-28688 * |
| J. ORG. CHEM., vol. 60, 1995, pages 3750 |
| J. PRAKT. CHEM., vol. 5, 1990, pages 332 |
| JUHASZ, L. ET AL.: "Synthesis and glycogen phosphorylase inhibitor activity of 2, 3- dihydrobenzo [1, 4] dioxin derivatives", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 15, no. 12, 2007, pages 4048 - 4056, XP022062537, DOI: 10.1016/j.bmc.2007.03.084 * |
| ORG. PROC. RES. DEV., vol. 9, no. 2, 2005, pages 141 |
| SYNTHESIS, 1979, pages 376 |
| T. W. GREENP.G.M. WUTS: "Protective Groups in Organic Synthesis", 2006, JOHN WILEY & SONS, INC. |
| VILLEMIN, D. ET AL.: "Solventless convenient synthesis of new cyano-2-aminopyridine derivatives from enamino nitriles", TETRAHEDRON LETTERS, vol. 54, no. 13, 2013, pages 1664 - 1668, XP055357314 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023090337A1 (ja) | 2021-11-19 | 2023-05-25 | 日本曹達株式会社 | 2-ヘテロアリールピリジン化合物の製造方法 |
| WO2024105900A1 (ja) | 2021-11-19 | 2024-05-23 | 日本曹達株式会社 | 2-ヘテロアリールピリジン化合物の製造方法 |
| EP4620953A1 (en) | 2021-11-19 | 2025-09-24 | Nippon Soda Co., Ltd. | Method for producing 2-heteroarylpyridine compound |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2925365T3 (es) | 2022-10-17 |
| JP2023159297A (ja) | 2023-10-31 |
| AU2019299152A2 (en) | 2021-03-11 |
| TWI840378B (zh) | 2024-05-01 |
| TW202005962A (zh) | 2020-02-01 |
| AU2019299152A1 (en) | 2021-03-04 |
| CA3105328A1 (en) | 2020-01-09 |
| EP3819296B1 (en) | 2022-06-29 |
| EP3819296A4 (en) | 2021-06-09 |
| IL279070B1 (en) | 2024-01-01 |
| IL279070B2 (en) | 2024-05-01 |
| US11999724B2 (en) | 2024-06-04 |
| JP7337058B2 (ja) | 2023-09-01 |
| CN112368271A (zh) | 2021-02-12 |
| IL279070A (en) | 2021-01-31 |
| EP3819296A1 (en) | 2021-05-12 |
| US20210188823A1 (en) | 2021-06-24 |
| JPWO2020009132A1 (ja) | 2021-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11629153B2 (en) | Forms and compositions of a MK2 inhibitor | |
| AU2015414743B2 (en) | Process for the preparation of kinase inhibitors and intermediates thereof | |
| CN110214139B (zh) | 用于生产三唑并吡啶化合物的方法 | |
| ES2963447T3 (es) | Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble | |
| JP2023159297A (ja) | ジアリールピリジン誘導体の製造方法 | |
| JP2020535193A (ja) | 結晶のリナグリプチン中間体およびリナグリプチンの調製のためのプロセス | |
| JP2020530497A (ja) | 3−(5−フルオロベンゾフラン−3−イル)−4−(5−メチル−5H−[1,3]ジオキソロ[4,5−f]インドール−7−イル)ピロール−2,5−ジオンの固体形態 | |
| JP2019524750A (ja) | 置換n−[2−(4−フェノキシピペリジン−1−イル)−2−(1,3−チアゾール−5−イル)エチル]ベンズアミドおよびn−[2−(4−ベンジルオキシピペリジン−1−イル)−2−(1,3−チアゾール−5−イル)エチル]ベンズアミド誘導体p2x7受容体アンタゴニスト | |
| JP2020536944A (ja) | 3−(5−フルオロベンゾフラン−3−イル)−4−(5−メチル−5H−[1,3]ジオキソロ[4,5−f]インドール−7−イル)ピロール−2,5−ジオンの固体形態 | |
| JP6165335B2 (ja) | ゲフィチニブの新規な結晶形およびその製造方法 | |
| JPWO2003055885A1 (ja) | 三環性トリアゾロベンゾアゼピン誘導体の新規結晶性物質 | |
| JP2012516327A (ja) | カルボキシ含有ピラゾールアミド化合物を製造するための新規な方法 | |
| CN111989331B (zh) | 2-[(2S)-1-氮杂双环[2.2.2]辛-2-基]-6-(3-甲基-1H-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3H)-酮的合成方法 | |
| KR20250174948A (ko) | 질소 함유 테트라시클릭 화합물의 결정 형태 및 이의 제조 방법 | |
| HK40047091A (en) | Method for producing diarylpyridine derivatives | |
| KR20240089380A (ko) | 마보릭사포의 합성 및 그 중간체 | |
| JPH01242585A (ja) | ベンゾフロ〔3,2−c〕キノリン誘導体の製造方法 | |
| BR112019010017B1 (pt) | Método para produção de composto de triazolopiridina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19831009 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 279070 Country of ref document: IL |
|
| ENP | Entry into the national phase |
Ref document number: 2020529019 Country of ref document: JP Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 3105328 Country of ref document: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2019831009 Country of ref document: EP Effective date: 20210204 |
|
| ENP | Entry into the national phase |
Ref document number: 2019299152 Country of ref document: AU Date of ref document: 20190703 Kind code of ref document: A |



































